Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Endocrine Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Endocrine Neoplasm

Cancer Family

Endocrine Neoplasm

CI-CAN-00000015Explore in graph →

Non-malignant764 active trials16 approved drugs64 evidence items

NCIt: C3010

Overview
Statistics
Survival
Genomics20
Variants & evidence64
Drugs26
Trials2724
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (60)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–25 of 60 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
· N Engl J Med · 2023 · PMID 37870969 · validated civic_curation pubmed
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
· N Engl J Med · 2020 · PMID 32846061 · validated civic_curation pubmed
Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
· Horm Metab Res · 2014 · PMID 24570209 · validated civic_curation pubmed
The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
· Clin Endocrinol (Oxf) · 2014 · PMID 24354346 · validated civic_curation pubmed
BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
· J Clin Oncol · 2014 · PMID 25024077 · validated civic_curation pubmed
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
· J Clin Invest · 2005 · PMID 15630448 · validated civic_curation pubmed
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
· J Clin Endocrinol Metab · 2008 · PMID 18682506 · validated civic_curation pubmed

Showing 1–25 of 60 publications

← Previous
1
2
3
Next →

When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?

· Ann Surg Oncol · 2009 · PMID 19472011 · validated civic_curation pubmed

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.

· Cancer · 2016 · PMID 27525386 · validated civic_curation pubmed

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

· Lancet Oncol · 2016 · PMID 27460442 · validated civic_curation pubmed

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

· J Clin Endocrinol Metab · 2005 · PMID 16174717 · validated civic_curation pubmed

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

· J Clin Endocrinol Metab · 2008 · PMID 18073307 · validated civic_curation pubmed

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.

· Ann Surg Oncol · 2011 · PMID 21594703 · validated civic_curation pubmed

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma.

· Oncol Lett · 2014 · PMID 24396464 · validated civic_curation pubmed

The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.

· Thyroid · 2012 · PMID 22650231 · validated civic_curation pubmed

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

· J Clin Endocrinol Metab · 2003 · PMID 12727991 · validated civic_curation pubmed

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.

· Oncotarget · 2016 · PMID 27086918 · validated civic_curation pubmed

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.

· J Clin Oncol · 2010 · PMID 20368568 · validated civic_curation pubmed

The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

· Cancer · 2012 · PMID 21882184 · validated civic_curation pubmed

NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.

· Cancer · 2016 · PMID 26784937 · validated civic_curation pubmed

Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.

· Endocr Relat Cancer · 2015 · PMID 25376618 · validated civic_curation pubmed

Re: "A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion" by Wijewardene et al.

· Thyroid · 2023 · PMID 37376747 · validated civic_curation pubmed

Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan.

· Jpn J Clin Oncol · 1998 · PMID 9839497 · validated civic_curation pubmed

Mutation and methylation analysis of TP53 in adrenal carcinogenesis.

· Eur J Surg Oncol · 2005 · PMID 15922892 · validated civic_curation pubmed

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

· N Engl J Med · 2016 · PMID 27093365 · validated civic_curation pubmed